Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study to Evaluate the Safety and Efficacy of Saizen® in Children With Idiopathic Short Stature (ISS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than or equal to 5 years~* Pre-pubertal; testicular volume less than 4 milliliter (in males) and breast Stage 1 (in females)~* The official records of height (for example records measured in hospitals or schools) during previous 6 months or more preceding inclusion in the study (self-measurement of the height at home will not be considered as a valid record)~* Height less than or equal to 3rd percentile compared to same sex, same age~* Peak serum growth hormone (GH) greater than 10 microgram per liter (mcg/L) in GH stimulation test (results of peak serum GH greater than 10 mcg/L in GH stimulation test within 1 year can be used instead)~* Naive to GH therapy~* Normal birth weight (that is greater than or equal to 3rd percentile when compared to same sex)~* Normal thyroid function~* Normal karyotype in girls~* Written informed consent from parent/guardian~* Written informed consent from the subject who speaks, understand, read, and write Korean~* Bone age less than 10 years in boys and less than 9 years in girls, whose difference between the bone and chronological age is no more than 3 years~Exclusion Criteria:~* Puberty development (Tanner stage greater than or equal to 2)~* Skeletal dysplasia or abnormal body proportions~* Chronic systemic illness~* Dysmorphic syndrome~* Growth Hormone Deficiency~* Small for Gestational Age (SGA)~* Current medication for Attention deficit hyperactivity disorder (ADHD) or hyperactivity disorder~* Current medication with drugs that may influence secretion or action of growth hormone (such as estrogen, androgen, anabolic steroid, corticosteroid, thyroxine, aromatase inhibitors)~* Diabetes mellitus~* Kidney transplantation~* Acute critical illness, including complications following open heart surgery, abdominal surgery or multiple accidental trauma~* Acute respiratory failure~* Malignancy or previous therapy for malignancy~* Known hypersensitivity to somatotropin or any of its excipients including cresol or glycerol~* Closed epiphyses, progression or recurrence of an underlying intracranial tumor, chronic renal disease~* Endocrinologic or metabolic disorders such as Prader-Willi syndrome; Russel-Silver syndrome; Seckel syndrome; Down syndrome; Cushing syndrome; Noonan syndrome; short stature caused by other chromosomal abnormalities~* The disorders that explain short stature such as psychiatric disorders, nutritional disorders, and chronic debilitating diseases~* Participation in another clinical trial within the past 3 months~* Status of legal incapacity or limited legal capacity of the parents or legal guardian

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Saizen Test Group (Type: EXPERIMENTAL): None
- Saizen Control Group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete